Decipher Labs Limited Submits Quarterly Compliance Certificate to BSE for Q4 FY26

1 min read     Updated on 17 Apr 2026, 05:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Decipher Labs Limited filed its quarterly compliance certificate with BSE under SEBI Regulation 74(5) for Q4 FY26 ended March 31, 2026. The certificate, signed by Whole-time Director Dalavath Amarsingh on April 17, 2026, confirms compliance with securities dematerialization reporting requirements. The company's RTA, Venture Capital and Corporate Investments Private Limited, certified that no securities were processed for dematerialization or rematerialization during the quarter.

powered bylight_fuzz_icon
37974091

*this image is generated using AI for illustrative purposes only.

Decipher Labs Limited has submitted its quarterly compliance certificate to BSE Limited under SEBI regulations for the quarter ended March 31, 2026. The filing demonstrates the company's adherence to regulatory requirements for securities dematerialization reporting.

Regulatory Compliance Filing

The compliance certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018. Whole-time Director Dalavath Amarsingh digitally signed the document on April 17, 2026, confirming that all required details have been furnished to stock exchanges where the company's shares are listed.

Parameter: Details
Filing Date: April 17, 2026
Quarter Ended: March 31, 2026
Scrip Code: 524752
Signatory: Dalavath Amarsingh (DIN-02206249)
Designation: Whole-time Director

RTA Confirmation

Venture Capital and Corporate Investments Private Limited, serving as the company's registrar and transfer agent, provided confirmation on April 6, 2026. The RTA certified that no securities were received for dematerialization or rematerialization during the quarter ended March 31, 2026.

Company Information

Decipher Labs Limited operates from its registered office located at A2, Q2, 5th floor, Cyber Towers, Hitech City, Madhapur, Hyderabad – 500081. The company maintains its listing compliance through regular filings with BSE Limited and other applicable stock exchanges.

The quarterly compliance certificate ensures transparency in securities handling and maintains investor confidence through proper regulatory adherence. This filing represents part of the company's ongoing commitment to meet SEBI's regulatory framework for listed entities.

Historical Stock Returns for Decipher Labs

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-2.21%+23.11%-21.20%-33.54%-78.07%

What factors might explain the absence of any dematerialization or rematerialization activity during Q1 2026, and could this indicate changes in investor sentiment?

How might Decipher Labs' business operations evolve given their consistent regulatory compliance track record in the technology sector?

Will the company consider expanding its stock exchange listings beyond BSE to improve liquidity and market access?

Decipher Labs Limited Announces Q3FY26 Financial Results Under Regulation 33

2 min read     Updated on 12 Feb 2026, 05:31 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Decipher Labs Limited officially announced its Q3FY26 financial results through a board meeting and regulatory filing to BSE. The company reported mixed performance with standalone revenue declining to ₹13.40 lakhs from ₹16.00 lakhs YoY, while consolidated revenue dropped significantly to ₹321.26 lakhs from ₹580.47 lakhs. Despite revenue declines, the company showed improvement in loss reduction with standalone net loss decreasing to ₹1.41 lakhs from ₹8.97 lakhs and consolidated net loss reducing to ₹53.88 lakhs from ₹59.27 lakhs YoY.

powered bylight_fuzz_icon
32442612

*this image is generated using AI for illustrative purposes only.

Decipher Labs Limited officially announced its unaudited financial results for the third quarter ended December 31, 2025, following a Board of Directors meeting held on February 12, 2026. The company submitted its quarterly results to BSE Limited under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Outcome and Regulatory Compliance

The Board of Directors meeting commenced at 3:30 PM and concluded at 4:30 PM at the company's registered office. The board approved both standalone and consolidated unaudited financial results along with the corresponding Limited Review Reports for the quarter and nine months ended December 31, 2025.

Meeting Details: Information
Date: February 12, 2026
Time: 3:30 PM - 4:30 PM
Venue: Registered Office
Scrip Code: 524752

Standalone Financial Performance

The company's standalone operations demonstrated mixed results with revenue decline but improved loss position during Q3FY26.

Metric: Q3FY26 Q3FY25 Change
Revenue from Operations: ₹13.40 lakhs ₹16.00 lakhs Decline
Total Income: ₹13.40 lakhs ₹16.33 lakhs Decline
Net Loss: ₹1.41 lakhs ₹8.97 lakhs Reduced Loss
Basic EPS: ₹(0.01) ₹(0.09) Improved

For the nine months ended December 31, 2025, standalone revenue from operations reached ₹106.85 lakhs compared to ₹62.72 lakhs in the corresponding previous period, indicating growth over the longer term despite quarterly decline.

Consolidated Financial Results

The consolidated results, incorporating subsidiaries Decipher Software Solutions LLC, USA and Decipher W.L.L., Bahrain, showed significant revenue contraction but maintained loss reduction trends.

Metric: Q3FY26 Q3FY25 Change
Revenue from Operations: ₹321.26 lakhs ₹580.47 lakhs Significant Decline
Total Revenue: ₹322.81 lakhs ₹597.34 lakhs Decline
Net Loss: ₹53.88 lakhs ₹59.27 lakhs Reduced Loss
Basic EPS: ₹(0.53) ₹(0.59) Improved

For the nine-month period, consolidated revenue from operations declined to ₹1,045.00 lakhs from ₹1,911.24 lakhs in the previous year, while net loss widened to ₹394.54 lakhs from ₹97.41 lakhs.

Segment Performance Analysis

The company operates through two distinct business segments with varying performance trajectories:

Segment: Q3FY26 Revenue Q3FY25 Revenue Nine Months FY26
Pharmaceutical Drugs: Nil ₹16.00 lakhs ₹67.50 lakhs
Consultancy Services (Standalone): ₹13.40 lakhs Nil ₹39.35 lakhs
Consultancy Services (Consolidated): ₹321.26 lakhs ₹564.47 lakhs ₹977.50 lakhs

Regulatory Updates and Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by the Audit Committee. The company acknowledged the implementation of New Labour Codes effective from November 21, 2025, stating no estimated liability for own employees while evaluating potential impacts on contract workforce.

Employee benefits expense remained the largest cost component on consolidated basis at ₹353.51 lakhs for Q3FY26 compared to ₹582.82 lakhs in Q3FY25. The company maintained its paid-up equity share capital at ₹1,010.00 lakhs with a face value of ₹10 per share across all reporting periods.

Historical Stock Returns for Decipher Labs

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-2.21%+23.11%-21.20%-33.54%-78.07%

More News on Decipher Labs

1 Year Returns:-33.54%